Table 8.
PROGRESS DrotAA mortality and clinical outcomes
| Variable |
DrotAA n = 882 |
Non-DrotAA n = 11,610 |
Total n = 12,492 |
P value |
| Discharge location by DrotAA use, n (%): | (n = 807) | (n = 10,537) | (n = 11,344) | <0.001 |
| Died | 400 (49.6) | 5236 (49.7) | 5636 (49.7) | |
| Community | 236 (29.2) | 3652 (34.7) | 3888 (34.3) | |
| Other hospital | 73 (9.0) | 856 (8.1) | 929 (8.2) | |
| Extended/Chronic care Institution | 83 (10.3) | 620 (5.9) | 703 (6.2) | |
| Other/Unknown | 15 (1.9) | 173 (1.6) | 188 (1.7) | |
| Hospital mortality for DrotAA therapy, adjusted for Age, 7 OD*, Active Cancer, and Propensity Quartiles† | Adjusted Odds Ratio | 95% Confidence Interval | ---- | P value |
| All patients** | 0.72 | 0.603 – 0.86 | ---- | 0.0003 |
*Organ Dysfunction (OD).
† See METHODS and Additional data file 1 for details and explanation of this covariate
** Model #9 used for this analysis.
DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis.